Amandine Bouillenne, Pascale Quatresooz, Patrick Collins, Arjen F Nikkels
{"title":"Retro- and prospective histologic and immunohistochemical analysis of safety margins following complete excision of less than 1 mm melanomas.","authors":"Amandine Bouillenne, Pascale Quatresooz, Patrick Collins, Arjen F Nikkels","doi":"10.1097/CMR.0000000000001070","DOIUrl":null,"url":null,"abstract":"<p><p>Reexcisions for melanoma do rarely present residual melanoma. To analyze the number of positive margins in reexcisions of in situ and <1 mm melanomas. To see whether the immunohistochemical (IHC) panel (Preferentially expressed antigen of melanoma (PRAME), Sry-related HMg-Box gene 10 (SOX 10), Human melanoma black 45 (HMB45), and Melan A) detected additional cases of melanoma. Three pilot cohorts (retrospective, prospective, and direct safety margins) were analyzed on the persistence of melanoma in reexcisions. Among the 97 cases of the retrospective cohort (27 in situ and 69 invasive melanomas), one residual in situ melanoma was detected in the reexcisions. In the second cohort, among 81 cases (18 in situ and 63 invasive melanomas), two cases (2.5%) presented in situ melanoma. In the group where direct margins were taken ( n = 21) 2 (9.5%) in situ melanoma were evidenced in the margins. The IHC panel was needed to confirm three additional in situ melanomas in cohort 2. In a total of 178 cases (97 + 81) of reexcision, three and five cases (1.7 and 3.4%) of in situ melanoma were evidenced after H/E and IHC, respectively. These pilot data could question the usefulness of reexcision in <1 mm melanomas, particularly as only cases of in situ melanoma were detected. Larges prospective series would be required to answer this issue.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"54-57"},"PeriodicalIF":1.8000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12736408/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CMR.0000000000001070","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Reexcisions for melanoma do rarely present residual melanoma. To analyze the number of positive margins in reexcisions of in situ and <1 mm melanomas. To see whether the immunohistochemical (IHC) panel (Preferentially expressed antigen of melanoma (PRAME), Sry-related HMg-Box gene 10 (SOX 10), Human melanoma black 45 (HMB45), and Melan A) detected additional cases of melanoma. Three pilot cohorts (retrospective, prospective, and direct safety margins) were analyzed on the persistence of melanoma in reexcisions. Among the 97 cases of the retrospective cohort (27 in situ and 69 invasive melanomas), one residual in situ melanoma was detected in the reexcisions. In the second cohort, among 81 cases (18 in situ and 63 invasive melanomas), two cases (2.5%) presented in situ melanoma. In the group where direct margins were taken ( n = 21) 2 (9.5%) in situ melanoma were evidenced in the margins. The IHC panel was needed to confirm three additional in situ melanomas in cohort 2. In a total of 178 cases (97 + 81) of reexcision, three and five cases (1.7 and 3.4%) of in situ melanoma were evidenced after H/E and IHC, respectively. These pilot data could question the usefulness of reexcision in <1 mm melanomas, particularly as only cases of in situ melanoma were detected. Larges prospective series would be required to answer this issue.
期刊介绍:
Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.